Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Amsterdam UMC | OTHER |
| Erasmus Medical Center | OTHER |
| Leiden University Medical Center | OTHER |
Not provided
Not provided
Not provided
The purpose of this study is to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) changes in terms of steatosis and elasticity in patients with morbid obesity 1, 3 and 5 years after bariatric surgery.
In addition, genomics, microbiome and metabolomics analyses will be carried out.
After being informed about the study and potential risks, 300 eligible patients will be included.
All participants will undergo lifestyle intervention before bariatric surgery. Extensive cardiometabolic analyses will be carried out. At 5 different moments (twice before and 3 times after bariatric surgery), liver steatosis and elasticity will be evaluate using Fibroscan. For those with an elevated liver fibrosis measurement (TE ≥7.2 kilopascal with M probe or ≥7.95 kilopascal with extra large probe), a laparoscopic liver biopsy will be performed during surgery. Patients will undergo gastric sleeve resection, Roux-n-Y gastric bypass or gastric minibypass.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FONS group | Patients with morbid obesity enrolled for bariatric surgery in the Franciscus Gasthuis, Rotterdam, the Netherland |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NASH screening | Diagnostic Test | Evaluate liver steatosis and elasticity using transient elastography in the FONS group |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in liver steatosis (in decibel/meter) 5 years after bariatric surgery | Transient elastography is a non invasive test evaluating liver steatosis | baseline (enrolment) and 5 years after bariatric surgery |
| Change from baseline in liver fibrosis (in kilopascal) 5 years after bariatric surgery | Transient elastography is a non invasive test evaluating liver fibrosis | baseline (enrolment) and 5 years after bariatric surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in liver steatosis (in decibel/meter) after lifestyle intervention | Transient elastography is a non invasive test evaluating liver steatosis | baseline (enrolment) and 3 months later |
| Change from baseline in liver fibrosis (in kilopascal) after lifestyle intervention |
Not provided
Inclusion Criteria:
Participants must fulfil all of the inclusion criteria (unless otherwise specified) for enrolment in the study.
The cardiac function of a subset group of 30 subjects aged 35 years and older with low transient elastography measurements (≤F1) and no known cardiac disease, hypertension or diabetes mellitus will be compared with a similar number of patients with high transient elastography measurements (≥F3) and no known cardiac disease, hypertension or diabetes mellitus. These patients will be consecutively included.
The investigators will perform a liver biopsy during endoscopic bariatric surgery in the patients with an elevated transient elastography measurement (≥F2; suggesting fibrosis and therefore the presence of NASH) in order to correlate the histological diagnosis to the clinical diagnosis based on elastography. In those patients in whom the diagnosis of NASH is confirmed by histology, more detailed follow up in a separate program at the department of gastroenterology is indicated according to the current guidelines.
Exclusion Criteria:
Patients who meet any of the following criteria at screening (unless otherwise specified) will be excluded from the study:
Participants younger than 18 years or older than 65 years
Participants with an established diagnosis of liver pathology like, but not limited to:
Histologically documented liver cirrhosis (fibrosis stage F4), at screening or in a historical biopsy.
Participants with active HIV infection and/or treatment.
Participants with diagnosed malignancies with or without active treatment.
Participants with a history or evidence of any other clinically significant condition or planned or expected procedure that in the opinion of the investigator, may compromise the patient's safety or ability to complete the study.
The participant does not understand Dutch.
Not provided
Not provided
Participants with morbid obesity enrolled for bariatric surgery at the Franciscus Gasthuis, Rotterdam, the Netherlands.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Franciscus Gasthuis | Rotterdam | South Holland | 3045PM | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37400234 | Derived | Theel WB, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EF, Kanhai DA, Apers JA, van Dalen BM, De Knegt RJ, Neecke B, van der Zwan EM, Grobbee DE, Hankemeier T, Wiebolt J, Castro Cabezas M. Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study. BMJ Open. 2023 Jul 3;13(7):e070431. doi: 10.1136/bmjopen-2022-070431. |
Not provided
Not provided
Data are available upon reasonable request. The data that will be shared is individual participant data that underlie the results reported in the study, after deidentification (text, tables, figures and appendices). Also, the study protocol will be available. Data will be available beginning 9 months and ending 36 months following publication, for researchers who provide a methodologically sound proposal for any purpose. Proposals may be directed to w.theel@franciscus. nl up to 36 months following article publication. After 36 months, the data will be available in our hospital's data warehouse but without investigator support other than deposited metadata.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D065626 | Non-alcoholic Fatty Liver Disease |
| D009767 | Obesity, Morbid |
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D009765 | Obesity |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood Feces
| Cardiac dysfunction screening | Diagnostic Test | Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography |
|
| Liver biopsy | Diagnostic Test | For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure. |
|
Transient elastography is a non invasive test evaluating liver fibrosis |
| baseline (enrolment) and 3 months later |
| Change from baseline in liver steatosis (in decibel/meter) 1 year after bariatric surgery | Transient elastography is a non invasive test evaluating liver steatosis | baseline (enrolment) and 1 year after bariatric surgery |
| Change from baseline in liver fibrosis (in kilopascal) 1 year after bariatric surgery | Transient elastography is a non invasive test evaluating liver fibrosis | baseline (enrolment) and 1 year after bariatric surgery |
| Change from baseline in liver steatosis (in decibel/meter) 3 years after bariatric surgery | Transient elastography is a non invasive test evaluating liver steatosis | baseline (enrolment) and 3 years after bariatric surgery |
| Change from baseline in liver fibrosis (in kilopascal) 3 years after bariatric surgery | Transient elastography is a non invasive test evaluating liver fibrosis | baseline (enrolment) and 3 years after bariatric surgery |
| Change from baseline in liver steatosis (in decibel/meter) according to the type of bariatric surgery | To evaluate if the type of bariatric surgery (gastric sleeve resection, Roux-en-Y Gastric bypass, Gastric minibypass) influences the steatosis in patients with morbid obesity, measured 1 and 3 years after bariatric surgery, adjusted for baseline steatosis/elasticity. | baseline and 1 and 3 years after bariatric surgery |
| Change from baseline in liver fibrosis (in kilopascal) according to the type of bariatric surgery | To evaluate if the type of bariatric surgery (gastric sleeve resection, Roux-en-Y Gastric bypass, Gastric minibypass) influences the elasticity in patients with morbid obesity, measured 1 and 3 years after bariatric surgery, adjusted for baseline steatosis/elasticity. | baseline and 1 and 3 years after bariatric surgery |
| Change from baseline in liver steatosis (in decibel/meter) according to the genetic profile | To determine if candidate genetic markers (PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13) are associated to changes in NAFLD/NASH severity in patients with morbid obesity one year after bariatric surgery. | baseline and 1 year after surgery |
| Change from baseline in liver fibrosis (in kilopascal) according to the genetic profile | To determine if candidate genetic markers (PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13) are associated to changes in NAFLD/NASH severity in patients with morbid obesity one year after bariatric surgery. | baseline and 1 year after surgery |
| Change from baseline in liver steatosis (in decibel/meter) according to gender and ethnicities | To determine if liver steatosis differs between gender or ethnicities before bariatric surgery and the changes 1, 3 and 5 years after bariatric surgery | baseline and 1, 3 and 5 years after bariatric surgery |
| Change from baseline in liver fibrosis (in kilopascal) according to gender and ethnicities | To determine if liver elasticity differs between gender or ethnicities before bariatric surgery and the changes 1, 3 and 5 years after bariatric surgery | baseline and 1, 3 and 5 years after bariatric surgery |
| Change from baseline in liver steatosis liver steatosis (in decibel/meter) according to the gut microbiota | To investigate the change in the ratio of Firmicutes/Bacteroides in the distal gut microbiota in patients with morbid obesity with NAFLD/NASH 1 year after bariatric surgery and the effects of these changes on transient elastography measurements. | baseline and 1 year after bariatric surgery |
| Change from baseline in liver steatosis liver fibrosis (in kilopascal) according to the gut microbiota | To investigate the change in the ratio of Firmicutes/Bacteroides in the distal gut microbiota in patients with morbid obesity with NAFLD/NASH 1 year after bariatric surgery and the effects of these changes on transient elastography measurements. | baseline and 1 year after bariatric surgery |
| Association between NAFLD/NASH and vascular dysfunction | To determine if the presence of NAFLD/NASH before bariatric surgery is associated with (subclinical) vascular dysfunction using the carotid intima media thickness and pulse wave velocity | baseline |
| Association between NAFLD/NASH and cardiac dysfunction | To determine if the presence of NAFLD/NASH before bariatric surgery is associated with (subclinical) cardiac dysfunction using transthoracic echocardiography | baseline and 1 year after bariatric surgery |
| Association between change in NAFLD/NASH and change in cardiac dysfunction | To determine if change of liver fibrosis stage is associated to change in cardiac function 1 year after bariatric surgery | baseline and 1 year after bariatric surgery |
| Correlation between histology and transient elastography measurement in a population with morbid obesity | To establish the correlation between histology (liver biopsy) and transient elastography measurement in a population with morbid obesity | during surgery |
| D050177 |
| Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |